John has been covering financial markets since before the FTSE 100 existed, starting out on the Industries and Commodities team at Dun & Bradstreet, before moving on to Datastream, where he was head of the news team for several years. After a succession of management roles at Thomson Reuters he returned to front-line journalism in 2006. Prior to joining Proactive Investors he was managing editor at Sharecast.
"I am delighted with the reciprocal arrangements that we have put in place with Glythera allowing both companies to develop Affimer-Permalink drug conjugates," said Avacta's CEO, Alastair Smith
VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours
Look at what you could have won...borrowing Bullseye host Jim Bowen's catchphrase, stock-picker-in-residence John Harrington looks at the winners (and losers) of the blue-chip index
Crossbeta has developed an innovative technology to generate stable oligomers for drug discovery and development in disease areas characterized by the presence of misfolded proteins, such as Alzheimer’s, Parkinson’s and Huntington’s disease
"We are encouraged by the first commercial sales of Vortex's VTX-1 Liquid Biopsy System and the continued expansion of ProAxsis' assay portfolio,” said Francois Martelet, the chief executive officer of NetScientific
In all, 16.05mln units were sold at a price of $2.15 each.
ValiRx confirms that there are no further obligations existing between itself and Yorkville
When chairman Ian Ross described the 12 months to the end of September as "extraordinary", he wasn't kidding
Described last week as the "mother of all binary punts", last week's purchase of Carillion backfired spectacularly and now the "Bombed Out" portfolio has lost half of its starting capital, which can mean only one thing ...
The short-sellers' favourite has turned up on the radar of the "Bombed Out but Bouncing Back" portfolio. Will it be the next Interserve?
Somewhat surprisingly, the portfolio is enjoying a good spell, but it is taking a bit of a leap of faith in terms of Tanzania with a couple of its new selections
A look back at the performance of the Stockpot Portfolios in 2017